Cargando…

Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis

Detalles Bibliográficos
Autores principales:	Lu, Xiaoyan, Jarrett, James, Sadler, Susannah, Tan, Min, Dennis, James, Jairath, Vipul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147798/ https://www.ncbi.nlm.nih.gov/pubmed/36934390 http://dx.doi.org/10.1007/s11096-023-01544-6

Ejemplares similares

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Kobayashi, Taku, et al.
Publicado: (2023)

Correction to: Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn’s Disease Receiving Biologics: A Retrospective Cohort Study
Publicado: (2022)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Correction to: Management of elderly ulcerative colitis in Japan
por: Higashiyama, Masaaki, et al.
Publicado: (2019)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Biological therapy for ulcerative colitis
por: Arora, Zubin, et al.
Publicado: (2015)

Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States
por: Afzali, Anita, et al.
Publicado: (2023)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Current and Emerging Biologics for Ulcerative Colitis
por: Park, Sung Chul, et al.
Publicado: (2015)

Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
por: Arivarasan, K, et al.
Publicado: (2016)

Transcriptomic Landscape of Treatment—Naïve Ulcerative Colitis
por: Taman, Hagar, et al.
Publicado: (2018)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Correction to: Identification and immunological characterization of cuproptosis-related molecular clusters in ulcerative colitis
por: Pu, Yunfei, et al.
Publicado: (2023)

Correction: Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
Publicado: (2023)

Correction to: Protective effect of 6-paradol in acetic acid-induced ulcerative colitis in rats
por: Rafeeq, Misbahuddin, et al.
Publicado: (2021)

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
por: Ohtaki, Yuichiro, et al.
Publicado: (2023)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Correction to: Answering biological questions by analysis of the strawberry metabolome
por: Haugeneder, Annika, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Hernandez, Luis, et al.
Publicado: (2019)

Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
por: Chu, Xinqiao, et al.
Publicado: (2023)

Correction The Journal of Cell Biology
Publicado: (1999)

Correction: Computational Biology in Colombia
por: Restrepo, Silvia, et al.
Publicado: (2009)

Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study
Publicado: (2019)

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
por: Lee, Hae Chan, et al.
Publicado: (2023)

Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis
por: Zhang, Di, et al.
Publicado: (2021)

Genome-wide DNA Methylation in Treatment-naïve Ulcerative Colitis
por: Taman, Hagar, et al.
Publicado: (2018)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
por: Fausel, Rebecca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vic4bd98jtkmvbibngc6or4lg0